在患有直肠出血的老年人群中使用血液稀释药物的管理:我们做得对吗?
Akshay Bavikatte1, Boby Sebastian1, Sade Uwaoma1
1West Suffolk NHS Foundation Trust, Bury Saint Edmunds, England, UK.
F1000Research
|June 28, 2024
概括
在血液稀释剂上有直肠出血的老年患者有不同的药物重新启动协议. 需要进行进一步的试验,以在胃肠道出血事件后标准化抗凝剂的管理.
科学领域:
- 胃肠病学 胃肠病学
- 老年病的医生 老年病的医生
- 药理学 药理学是指药理学的学科.
背景情况:
- 服用抗凝剂的老年患者的直肠出血存在重大管理挑战.
- 关于逆转药物和重新开始血液稀释药物的标准,存在有限的指导.
- 这项研究解决了在管理这些复杂案件时需要明确的需求.
研究的目的:
- 审查在服用血液稀释剂时经历直肠出血的老年患者的人口统计数据.
- 分析这些患者使用的管理策略.
- 调查重新开始抗凝药治疗的标准和结果.
主要方法:
- 从2018年1月到2020年12月,对60岁以上的患有直肠出血的患者进行了回顾性分析.
- 从电子记录中提取的数据,重点关注抗凝剂的使用和遵守指南.
- 评估患者的人口统计,诊断和药物管理,包括抗凝药重新开始.
主要成果:
- 包括93名老年患者 (平均年龄82岁);52%的患者有心房动,20%的患者以前曾经中风.
- 分心病是最常见的诊断.
- 抗凝剂的重新开始有所不同:DOAC患者在出院后重新开始服用39%,华法林患者62%,阿司匹林患者60%,所有克洛皮多格勒/双抗血小板药患者都重新开始服用.
结论:
- 在老年人直肠出血后重新开始服用血液稀释药物是高度个性化的.
- 目前的实践缺乏标准化,强调需要更广泛的临床试验.
- 进一步的研究是必不可少的,以建立在这个人群中用于抗凝剂管理的标准化协议.
相关概念视频
Esophageal Varices-II: Clinical Features and Management
57
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
57
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
675
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
675
Disorders of Hemostasis
831
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
831
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
517
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
517
Peptic Ulcer Disease IV: Management
87
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
87


